Pollen Counts At Claritin-D Study Sites Undermine 30-Minute Onset Claim
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Review Board decision shows that firms appealing recommendations by the National Advertising Division sometimes will receive different opinions from the appellate board of appointed experts, which considered appeals by both Bayer and Sanofi's Chattem from a NAD review.